TScan Therapeutics Stock Plummets After Halting Pivotal Trial, Slashing 75% of Workforce

Shares of TScan Therapeutics (NASDAQ: TCRX) plunged in morning trading after the company announced a sweeping strategic reorganization, highlighted by the immediate halt of its Phase 3 pivotal trial and a workforce reduction of approximately 75%.

Pivotal Trial Halted Amid Restructuring

TScan is immediately pausing enrollment in its ALLOHA-2™ pivotal trial, which was evaluating TSC-101 for patients with hematologic malignancies. The company cited insufficient capital as the primary reason for suspending the trial, a program that analysts had viewed as a core near-term value driver for the biotechnology firm.

The restructuring also involves the elimination of TScan’s internal manufacturing organization and a significant reduction of its research operations. The company projects these moves will generate cumulative cost savings of $55 million through the end of 2027.

Strategic Pivot to Solid Tumors

With its lead program on hold, TScan is redirecting its focus and resources toward two early-stage candidates for solid tumors. The company will advance its in vivo-engineered TCR-T therapies targeting PRAME and MAGE-A4 toward IND-enabling studies.

Ad

However, this strategic pivot significantly extends the company's clinical development timeline, with Phase 1 trials for these new candidates not targeted to begin until the fourth quarter of 2027. TScan's updated cash runway is now projected to last only into Q4 2027, and the company is actively seeking partners for its paused hematology and autoimmune programs.

Market Impact

The combination of a halted late-stage trial, a drastically shortened cash runway, and a pivot to unproven, early-stage assets triggered a sharp sell-off. TScan's stock fell nearly 28.8%, hitting a 52-week low of $0.45 intraday.

The move reflects a profound reset in investor expectations, as the company's near-term path to potential commercialization has been effectively dismantled. The broader market was largely flat, indicating the stock's collapse was a direct response to the company-specific news.